A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, 3 Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Symptom Response of REL-1017 (d-Methadone) in the Treatment of Patients With Major Depressive Disorder
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2018
At a glance
- Drugs Dextromethadone (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Proof of concept
- Sponsors Relmada Therapeutics
- 17 Jan 2018 According to a Relmada Therapeutics media release, patient enrollment is anticipated in the first half of 2018.
- 26 Sep 2017 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
- 26 Sep 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jul 2018.